



BETA DRUGS LIMITED

BDL/PKL/SEC/2025-26

14th February, 2026

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/I, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai — 400 051.

SYMBOL-BETA

Sub: Outcome of the Board Meeting held on Saturday, 14th February, 2026 – Q3 Results

Dear Sir/Madam,

Pursuant to Regulation 29, 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform that, the meeting of the Board of Directors held today, i.e. on **Saturday, 14th February, 2026**, commenced at 11:00 AM and concluded at 01:25 PM. The Board, inter-alia, discussed and approved the following:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025.
2. Noted the Limited Review Report (Standalone and Consolidated) issued by the Statutory Auditors, on the aforementioned Financial Results for the quarter and nine months ended December 31, 2025.

Enclosed the Unaudited Standalone Financial Results and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025, along with Limited Review Reports thereon.

This is for the information of all the stakeholders of the Company.

Thanking You

Your's faithfully

For Beta Drugs Ltd.

Beta Drugs Limited

Company Secretary
ACS - 24684

Rajni Brar

Company Secretary

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com



BETA DRUGS LIMITED

3RD QUARTER RESULTS OF BETA DRUGS LIMITED FOR FINANCIAL YEAR '25-'26

BDL recorded Total Revenues of INR 89.58 Crores for the quarter ended December 2025 with EBITDA of INR 19.28 Crores and Profit After Tax of INR 8.51 Crores. The EBITDA margins continue to remain robust at 22% and PAT margins at 9.5%.

The sales were flat for Quarter ended December 2025 as compared to the same period a year ago. However, the Gross Margin+ recorded a sharp increase to 59% in Q3FY26 from 52% year ago. The EBITDA margins were flat as Employee expenses grew by 21% compared to previous year on account senior level hiring in Regulatory, Manufacturing and QA/QC teams.

The Company recorded strong growth of 33% in own branded sales demonstrating increased traction of orals and higher margin products, however the overall sales were flat as sales in CDMO were affected since the Company decided to de-focus on Platins. In Exports, the sales were impacted as key tenders were pushed out and also due to geopolitical tensions in Latin America

The Interest expenses were INR 4.43 Crores, up from INR 1.87 Crores on account of the interest on CCD

OUTLOOK:

The Company is revising its outlook for the financial year ending March 2026 from INR 420 Crores to INR 400 Crores on account of the decision to de-focus its sales of Platins. The Company recorded Platin sales of INR 46.50 Crs. in FY25 and has clocked in sales of INR 31.60 Crs. in YTD Dec'25 with no additional sales of Platins expected in Q4FY26. The downward revision in the outlook is primarily attributable to lower Platin sales which has been a strategic reset for the Company to focus on higher margin products.

The Company expects to close FY27 with revenues of INR 530 Crs. with EBITDA margins at ~24% driven by higher growth in Own brands and Exports. In Own Brands, the Company expects to drive growth through new NDDS product launches and increased penetration of new accounts. Methotrexate Oral Solution, the first NDDS launch of the Company is expected to do sales of INR 13 Crs. in FY27 including own branded sales of INR 7 Crs. Two additional NDDS approvals are expected in FY27 which will drive sales from Q4 FY27. The growth in Exports will be driven primarily through commercialisation of product registrations in Algeria, Mexico and Philippines.

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@betadrugslimited.com

KHURANA SHARMA & COMPANY

CHARTERED ACCOUNTANTS

H.No. 1299, SECTOR 15-B, CHANDIGARH

PHONE : 9988070254, 9878029920

LIMITED REVIEW REPORT

INDEPENDENT AUDITOR'S REVIEW REPORT ON CONSOLIDATED UNAUDITED QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE FINANCIAL RESULTS FOR PERIOD ENDED ON 31ST DECEMBER, 2025 PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,
The Board of Directors
Beta Drugs Limited
Village Nandpur, Lodhimajra Road
Baddi, Distt. Solan
H.P. 174101

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **BETA DRUGS LIMITED** ("the Parent") and its subsidiary ("the Parent" and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax for the quarter ended 31st December, 2025 and year to date results for period ended on 31st December, 2025, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31st December, 2025 and the corresponding period from 01st April, 2025 to 31st December, 2025, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.


4. The Statement includes the unaudited results of the wholly owned subsidiary company: Adley Formulations Pvt Ltd, Adley Lab Limited and Beta Research Private Limited by management of the Company.

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Our conclusion is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim unaudited financial information/financial results of Adley Formulations Pvt Ltd (its subsidiary), Adley Lab Limited (its subsidiary) & Beta Research Private Limited (its subsidiary) which have not been reviewed/audited by their auditors, whose interim financial information/ financial results reflect total revenue of Rs.36,79,36,995.59 , Total net profit/(loss) after tax of Rs. 5,26,46,651.16 and total comprehensive income / loss of Rs. Nil, for the Qtr. ended 31st December, 2025, respectively. These financial results whose report have been furnished to us by the management and our opinion on the consolidated financial results in so far as it related to the amount and disclosure included in respect of this subsidiary is based solely on the reports of the management and procedure performed by us as stated in paragraph above.

For KHURANA SHARMA & CO.
Chartered Accountants


Signature
(CA VIBHOR KHURANA)
PARTNER M. NO. 568524
UDIN: 26568524ULLMEY1791

Place: Chandigarh
Date: 14.02.2026

BETA DRUGS LIMITED
Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969

Unaudited Consolidated Financial Results for the Quarter ended on 31st December' 2025

Particulars	3 Months Ended on 31.12.2025 (Unaudited)	3 Months Ended on 30.09.2025 (Unaudited)	3 Months Ended on 31.12.2024 (Unaudited)	9 Months Ended on 31.12.2025 (Unaudited)	9 Months Ended on 31.12.2024 (Unaudited)	Year Ended on 31.03.2025 (Audited)
I. Revenue From Operations	87,26,75,344.69	1,03,38,64,143.07	88,28,86,425.31	2,90,86,08,247.94	2,68,59,20,450.02	3,62,35,57,190.75
II. Other Income	2,30,96,689.86	2,98,76,825.26	96,84,528.23	8,28,53,560.65	2,47,44,539.14	6,43,65,534.46
III. Total Revenue (I+II)	89,57,72,034.55	1,06,37,40,968.33	89,25,70,953.54	2,99,14,61,808.59	2,71,06,64,989.16	3,68,79,22,725.21
IV. Expenses						
a) Cost of Materials Consumed	32,50,40,440.95	46,40,08,135.15	43,73,07,217.38	1,37,02,95,511.76	1,31,55,19,541.50	1,75,77,75,782.98
b) Purchase of Stock-in-Trade	-	-	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods/WIP	3,53,95,214.65	2,89,62,813.98	(1,44,53,410.10)	(1,94,60,071.27)	(4,16,12,642.18)	(4,42,42,936.65)
d) Employee benefit expenses	16,82,27,207.35	16,48,30,015.53	13,91,25,461.56	49,32,83,237.06	40,32,96,807.88	55,51,43,129.20
e) Finance Costs	4,43,43,039.51	3,61,21,494.89	1,87,68,311.50	11,36,68,523.09	3,70,38,854.59	6,98,91,090.10
f) Depreciation & amortisation expenses	4,38,93,299.95	4,24,01,265.91	3,23,73,946.63	12,35,55,843.58	8,94,66,719.54	12,51,40,320.80
g) Other expenses	17,41,52,457.14	16,29,82,058.87	13,63,82,374.33	48,44,95,058.84	43,61,25,142.30	60,88,30,676.05
Total Expenses	79,10,51,659.56	89,93,05,784.33	74,95,03,901.31	2,56,58,38,103.06	2,23,98,34,423.64	3,07,25,38,062.48
V. Profit before exceptional and extraordinary items and tax (III-IV)	10,47,20,374.99	16,44,35,184.00	14,30,67,052.23	42,56,23,705.53	47,08,30,565.52	61,53,84,662.73
VI. Exceptional Items (Pref. Issue)	-	-	2,34,72,812.00	-	2,34,72,812.00	4,56,95,656.00
VII. Profit before extraordinary items and tax (V-VI)	10,47,20,374.99	16,44,35,184.00	11,95,94,240.23	42,56,23,705.53	44,73,57,753.52	56,96,89,006.73
VIII. Extraordinary Items	-	-	-	-	-	-
IX. Profit before tax (VII-VIII)	10,47,20,374.99	16,44,35,184.00	11,95,94,240.23	42,56,23,705.53	44,73,57,753.52	56,96,89,006.73
X. Tax Expenses	1,95,47,807.72	4,22,55,730.20	3,01,16,717.34	10,12,85,970.58	11,35,16,274.46	14,55,03,499.51
XI. Profit (Loss) for the period from continuing operations (IX-X)	8,51,72,567.27	12,21,79,453.80	8,94,77,522.89	32,43,37,734.94	33,38,41,479.06	42,41,85,507.22
XII. Profit (Loss) from discounting operations	-	-	-	-	-	-
XIII. Tax expenses of discounting operations	-	-	-	-	-	-
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)	-	-	-	-	-	-
XV. Net Profit/(Loss) for the period (XI+XIV)	8,51,72,567.27	12,21,79,453.80	8,94,77,522.89	32,43,37,734.94	33,38,41,479.06	42,41,85,507.22
XVI. Earning per share						
a) Basic	8.40	12.10	9.31	32.00	34.73	42.02
b) Diluted	8.40	12.10	9.31	32.00	34.73	42.02
XVIII. Paid up equity share capital	10,13,68,900.00	10,09,45,530.00	9,61,37,900.00	10,13,68,900.00	9,61,37,900.00	10,09,45,530.00

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 14th February' 2026.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.
- The consolidated financial results include the unaudited financial results of the wholly owned subsidiaries: Adley Formulations Pvt Ltd, Adley Lab Limited and Beta Research Private Limited by management of the Company.

For KHURANA SHARMA & CO.

Chartered Accountants
(FRN : 010920N)

Chandigarh
No. 568524
CA VIBHOR KHURANA
PARTNER

Membership No. : 568524

UDIN: 26568524ULLMEY179

Place : Chandigarh

Date : 14-02-2026

RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

RAJNI BRAR
COMPANY SECRETARY
ACS24684

NIPUN ARORA
CFO
FCA514044

For and on Behalf of Board of Directors

KHURANA SHARMA & COMPANY

CHARTERED ACCOUNTANTS

H.No. 1299, SECTOR 15-B, CHANDIGARH

PHONE : 9988070254, 9878029920

LIMITED REVIEW REPORT

INDEPENDENT AUDITOR'S REVIEW REPORT ON STANDALONE UNAUDITED QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE FINANCIAL RESULTS FOR PERIOD ENDED ON 31ST DECEMBER, 2025 PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,
The Board of Directors
Beta Drugs Limited
Village Nandpur, Lodhimajra Road
Baddi, Distt. Solan
H.P. 174101

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **BETA DRUGS LIMITED** ("the Company"), for the quarter ended 31st December, 2025 and year to date results for period ended on 31st December, 2025, ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KHURANA SHARMA & CO.

Chartered Accountants



Signature

(CA VIBHOR KHURANA)

PARTNER M. NO. 568524

UDIN: 2656PS24AY COR2191

Place: Chandigarh

Date: 14.02.2026

BETA DRUGS LIMITED
Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205
Phone : 01795-236196 E-Mail : betabaddi@gmail.com
CIN No. L24230HP2005PLC028969
Unaudited Standalone Financial Results for the Quarter ended on 31st December' 2025

Particulars	3 Months Ended on 31.12.2025 (Unaudited)	3 Months Ended on 30.09.2025 (Unaudited)	3 Months Ended on 31.12.2024 (Unaudited)	9 Months Ended on 31.12.2025 (Unaudited)	9 Months Ended on 31.12.2024 (Unaudited)	Year Ended on 31/03/2025 (Audited)
I. Revenue From Operations	50,27,62,509.60	54,48,02,561.23	48,27,45,967.07	1,71,08,13,611.24	1,66,46,36,456.44	2,20,19,96,376.51
II. Other Income	2,50,72,529.36	2,74,34,350.40	88,07,037.48	8,22,55,468.29	2,26,45,306.00	6,19,16,105.34
III. Total Revenue (I+II)	52,78,35,038.96	57,22,36,911.63	49,15,53,004.55	1,79,30,69,079.53	1,68,72,81,762.44	2,26,39,12,481.85
IV. Expenses						
a) Cost of Materials Consumed	24,72,21,064.81	29,63,33,580.51	28,87,85,702.60	99,18,76,734.35	95,28,67,896.29	1,23,50,32,447.90
b) Purchase of Stock-in-Trade	-	-	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods/WIP	1,41,98,789.79	3,15,52,145.18	(2,38,22,993.27)	69,46,438.53	(5,02,12,871.16)	(3,70,41,494.89)
e) Employee benefit expenses	8,24,18,143.09	8,01,90,278.42	7,55,66,985.31	24,74,07,865.20	21,90,82,725.17	30,29,81,386.50
f) Finance Costs	3,17,15,990.99	2,97,36,836.68	1,33,13,786.36	8,93,27,992.71	1,94,93,922.87	4,75,55,848.66
g) Depreciation & amortisation expenses	2,50,91,608.02	2,38,19,510.26	1,92,18,201.06	6,92,93,760.70	5,30,45,275.33	7,44,20,337.55
h) Other expenses	9,34,54,567.21	8,93,92,539.81	8,49,97,064.75	27,66,94,614.19	28,12,34,135.09	38,68,63,166.05
Total Expenses	49,41,00,163.91	55,10,24,890.87	45,80,58,746.81	1,68,15,47,405.68	1,47,55,11,083.59	2,00,98,11,691.77
V. Profit before exceptional and extraordinary items and tax (III-IV)	3,37,34,875.05	2,12,12,020.76	3,34,94,257.74	11,15,21,673.85	21,17,70,678.85	25,41,00,790.08
VI.Exceptional Items (Pref. Issue)	-	-	2,34,72,812.00	-	2,34,72,812.00	4,56,95,656.00
VII. Profit before extraordinary items and tax (V-VI)	3,37,34,875.05	2,12,12,020.76	1,00,21,445.74	11,15,21,673.85	18,82,97,866.85	20,84,05,134.08
VIII.Extraordinary Items	-	-	-	-	-	-
IX. Profit before tax (VII-VIII)	3,37,34,875.05	2,12,12,020.76	1,00,21,445.74	11,15,21,673.85	18,82,97,866.85	20,84,05,134.08
X.Tax Expenses	12,08,958.93	60,66,122.74	25,22,196.64	2,15,13,822.58	4,79,19,989.04	5,40,83,732.59
XI. Profit (Loss) for the period from continuing operations (IX-X)	3,25,25,916.12	1,51,45,898.03	74,99,249.10	9,00,07,851.27	14,03,77,877.82	15,43,21,401.49
XII.Profit (Loss) from discounting operations	-	-	-	-	-	-
XIII. Tax expenses of dicounting operations	-	-	-	-	-	-
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)	-	-	-	-	-	-
XV. Net Profit/(Loss) for the period (XI+XIV)	3,25,25,916.12	1,51,45,898.03	74,99,249.10	9,00,07,851.27	14,03,77,877.82	15,43,21,401.49
XVI. Earning per share						
a) Basic	3.21	1.50	0.78	8.88	14.60	15.29
b) Diluted	3.21	1.50	0.78	8.88	14.60	15.29
XVIII. Paid up equity share captial	10,13,68,900.00	10,09,45,530.00	9,61,37,900.00	10,13,68,900.00	9,61,37,900.00	10,09,45,530.00

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held on 14th February' 2026.

2 The company is engaged in single business segment i.e. Pharmaceuticals.

3 Figures are regrouped/rearranged, wherever considered necessary.

For KHURANA SHARMA & CO.

Chartered Accountants

(FRN : 010920N)


CA VIBHOR KHURANA
PARTNER

Membership No. : 568524.

UDIN: 26568524A7CORE2191

Place : Chandigarh

Date : 14-02-2026


RAHUL BATRA
MANAGING DIRECTOR
DIN : 02229234

For and on Behalf of Board of Directors

RAJNI BRAR
COMPANY SECRETARY
ACS24684

NIPUN ARORA
CFO
FCA514044



BETA DRUGS LIMITED

BDL/PKL/SEC/2025-26

14th February, 2026

To
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot no. C/I, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051.

Sub: Certificate as per regulation 33(2) (a) of SEBI (LODR) Regulations, 2015

Dear Sir/Madam

We the undersigned, in our respective capacities as Managing Director and Chief Financial Officer of Beta Drugs Limited, certify that the Standalone and Consolidated Audited Financial results for the quarter and nine months ended December 31, 2025, do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

Thanking You
Yours faithfully

For Beta Drugs Limited


Mr. Rahul Batra
Managing Director
DIN: 02229234


Mr. Nipun Arora,
Chief Financial Officer

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134-114 Haryana (INDIA) Phone. +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com

E-Mail :- info@detadrugslimited.com